The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Abstract
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies in the 1980s also showed that IL-6 is produced by cardiac myxoma cells (42) and Castleman’s germinal center cells (43)”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [43]
In the citing paper
“Generally, surgical removal of hyperplastic lymph nodes results in symptomatic improvement and reduced serum IL-6 concentrations (Yoshizaki et al., 1989”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Yoshizaki et al., 1989
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Cited by
Sorted by citations
Items 401–489 of 489
Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish
Tanaka, T., & Narazaki, M. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000262 · Cited by 3
“Castleman’s disease is a chronic lymphoproliferative disorder in which persistent IL-6 production occurs in the germinal centers of swollen lymph node(s), indicating its pathological involvement (11).”
BackgroundRyu, W., Park, M.-H., Kim, H., Koh, I., & Kim, K. N. (2017) · Archives of Craniofacial Surgery · doi:10.7181/acfs.2017.18.2.122 · Cited by 2
“In earlier studies, patients with systemic symptoms and localized CD were shown to have a reduction in symptoms associated with decreased IL-6 levels following excision of the abnormal node [4,6].”
BackgroundBeşışık, S. K., Yonal-Hindilerden, İ., Hindilerden, F., Dogan, I., & Beşışık, F. (2016) · Turkish journal of haematology : official journal of Turkish Society of Haematology · doi:10.4274/tjh.2016.0083 · Cited by 2
“In CD, hepcidin secretion induced by IL-6 is the main cause of anemia [4,5].”
BackgroundSasaki, H., Maeda, T., Hara, Y., Osa, M., Imai, K., Moriguchi, K., Mikita, K., Fujikura, Y., Kaida, K., & Kawana, A. (2015) · International Journal of STD and AIDS · doi:10.1177/0956462414562050 · Cited by 2
[Multicentric Castleman disease not associated with HHV-8 and HIV viruses].
Forteski, D. D. F., Netto, F. C., Lomonte, A., dos Anjos, B. C. C., Zerbini, M., & Zerbini, C. A. D. F. (2014) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2013.05.004 · Cited by 2
A rare case of Castleman's disease presenting as a pulmonary mass mimicking pulmonary malignancy
Bashyal, R., Mc, L., Thakur, B., & Singh, L. (2011) · doi:10.3126/jpn.v1i1.4456 · Cited by 2
Polyneuropathy in Osteosclerotic Myeloma Coexisting With Hyaline Vascular Castleman's Disease.
Sahota, P., Das, C., Prabhakar, S., Rajwanshi, A., Singh, P., & Khurana, D. (2005) · Journal of Clinical Neuromuscular Disease · doi:10.1097/01.cnd.0000176975.38265.05 · Cited by 2
“lymph nodes in patients with Castleman’s disease.(14) They also found a close relationship”
BackgroundMulticentric Castleman's Disease Associated with Inherited Epidermolysis Bullosa
Kawakami, Y., Nishibu, A., Kikuchi, S., Ohtsuka, M., Nakamura, K., Nozawa, Y., Abe, M., Iwatsuki, K., & Kaneko, F. (2003) · Journal of dermatology (Print) · doi:10.1111/j.1346-8138.2003.tb00459.x · Cited by 2
Human Herpesvirus-8-Encoded Signalling Ligands and Receptors
Nicholas, J. (2003) · Journal of Biomedical Sciences · doi:10.1159/000072375 · Cited by 2
Does IL-6 mediate renal manifestations of Castleman's disease?
Fujigaki, Y., & Hishida, A. (2002) · Internal medicine · doi:10.2169/internalmedicine.41.1086 · Cited by 2
gp130-mediated signalling as a therapeutic target
Ohtani, T., Ishihara, K., Atsumi, T., Yoshida, Y., Nishida, K., Narimatsu, M., Shirogane, T., Hibi, M., & Hirano, T. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.4.459 · Cited by 2
“The overexpression of IL-6 has also been shown in connection with other diseases, including osteoporosis, Castleman’s disease and several autoimmune diseases [9,25,26].”
BackgroundAbarca, M., Andrade, R., García-Arjona, A., Escolar, J., Blanes, A., García-Hirschfeld, J., & González-Sántos, P. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005483308015 · Cited by 2
Ablashi, D., Armstrong, G., & Manaker, U. (1900) · New South Wales Public Health Bulletin Supplementary Series · doi:10.1071/nb04s38
Matsui, T., Kawagita, K., Nomura, K., Hamaguchi, M., Hashiba, N., Tsuji, N., Shibuya, H., Yamauchi, Y., Noguchi, D., Sato, K., et al. (2026) · Surgery Case Reports · doi:10.70352/scrj.cr.25-0497 · Cited by 1
Koga, T., Sumiyoshi, R., Shimizu, T., Hosogaya, N., Fukushima, C., Yamamoto, H., Yoshifuji, H., Higa, S., & Kawakami, A. (2025) · Cureus · doi:10.7759/cureus.98233 · Cited by 1
Maladie de Castleman avec manifestation systémique: à propos d’un cas
Hmimsa, A., Touihem, N., Attifi, H., & Hmidi, M. (2025) · The Pan African Medical Journal · doi:10.11604/pamj.2025.52.84.48274 · Cited by 1
Idiopathic multicentric Castleman disease resembling autoimmune diseases: A case report
Li, T., Yao, M.-Y., & Hou, Y. (2025) · Medicine · doi:10.1097/md.0000000000043320 · Cited by 1
“[5] The prognosis of iMCD varies depending on the severity of the individual’s condition and differences in medication.”
Fukui, S., Sumiyoshi, R., Koga, T., Hosogaya, N., Narita, S., Morimoto, S., Yano, H., Katsube, A., Yano, S., Masaki, Y., et al. (2025) · Cureus · doi:10.7759/cureus.78865 · Cited by 1
Idiopathic Multicentric Castleman's Disease as a Mimicker of IgG4-related Disease
Yoshimi, R., & Nakajima, H. (2024) · Internal medicine · doi:10.2169/internalmedicine.4793-24 · Cited by 1
Localized retroperitoneal mass suspected malignancy: A rare case of unicentric Castleman's disease
Alhariry, E. S., Hasan, A., Abdelghany, A., & Nafie, K. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9451 · Cited by 1
“11,12 Likewise, IL-6 secretion is stimulated by HHV-8 infection in case of multicenteric lesions, and several observations strongly suggest IL-6 as the key element contributing to the disease process; (1) Following the removal of the enlarged hyperplastic lymph node, there is a reduction in the…”
BackgroundComparison of pathophysiological differences in TAFRO syndrome with or without lymphadenopathy
Uchiyama, T., Yokoyama, A., Kuroda, Y., & Aoki, S. (2024) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.24026 · Cited by 1
“13,14 Therefore, some researchers consider TAFRO syndrome as a variant of iMCD.”
MethodInfluentialDiffuse cryptococcal pneumonia in multicentric Castleman’s disease with elevated serum IgG4
Takiguchi, J., Tomioka, H., Kamei, K., & Kawabata, Y. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-252595 · Cited by 1
Kojima, D., Yamaguchi, S., Hashiguchi, A., Hayashi, K., Uchiyama, K., Yoshimoto, N., Adachi, K., Nakayama, T., Nishioka, K., Tajima, T., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1037032 · Cited by 1
“Importantly, the pathogenesis is thought to be caused by overstimulation of the immune system by interleukin6 (IL-6) produced in the enlarged lymph nodes (10).”
BackgroundKhan, A. H., Rahaman, M. F. U., Rahman, S., Khan, M. M. R., & Sami, C. A. (2022) · Cureus · doi:10.7759/cureus.30323 · Cited by 1
“Most cases of HIV-associated CD are plasma cell or plasmablastic variations with more severe symptoms and a fast-advancing clinical history [5-11]”
BackgroundAchrane, J., Baina, S., Benamor, J., & Bourkadi, J. (2022) · Egyptian Journal of Chest Disease and Tuberculosis · doi:10.4103/ejcdt.ejcdt_79_20 · Cited by 1
Sugawara, E., Sato, T., Amasaki, Y., & Katsumata, K. (2022) · Medicine · doi:10.1097/md.0000000000028941 · Cited by 1
“Although the etiology of MCD remains unknown, IL-6, a proinflammatory cytokine, is thought to play a central role in the pathogenesis of MCD.([2]) Renal involvement associated withMCD has been described in a limited number of case reports and series.”
BackgroundInfluentialUlas, S. T., & Dasdelen, S. (2021) · Der Internist · doi:10.1007/s00108-021-01063-4 · Cited by 1
Castleman’s disease: an entity forgotten in ENT
Ali, M., Wadhwa, V., Meher, R., Tomar, R., Singh, K., & Singh, N. (2021) · International Journal of Otorhinolaryngology and Head and Neck Surgery · doi:10.18203/issn.2454-5929.ijohns20211593 · Cited by 1
“In a study conducted by Yoshizaki et al it was observed that there was an abrupt drop in interleukin 6 levels and resolution of symptom following removal of CD mass.(2) A similar study by Nishimoto et al on multicentric CD showed that treatment with IL-6 receptor antibody relieved symptoms and signs of the disease.”
ResultUnexplained Diffuse Lymphadenopathy in a Patient With HIV
Min, E. A., Palacios, C., Hardy, N., & Riedel, D. (2020) · doi:10.1097/ipc.0000000000000936 · Cited by 1
“Elevated serum levels of interleukin-6 are frequently found in these patients.(9) Nearly all PLHIVs with MCD have plasma HHV-8 viremia.”
BackgroundCastleman's Disease in an Adolescent
Singh, U., Nayak, M., Singh, S., & Shenoy, K. R. (2020) · Apollo Medicine · doi:10.4103/am.am_47_20 · Cited by 1
The Cytokine Interleukin 6 (IL-6) as a Neural and Endocrine Regulator
Castro, K. E. N., Méndez-García, L. A., Solleiro-Villavicencio, H., & Morales‐Montor, J. (2018) · Advances in Neuroimmune Biology · doi:10.3233/nib-180143 · Cited by 1
Therapeutic outlook for Castleman’s disease: prospects for the next decade
Koga, T., Fujimoto, S., Kawakami, A., Kawabata, H., Masaki, Y., Kishimoto, T., & Yoshizaki, K. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1348295 · Cited by 1
“the observation of excess IL-6 production was observed in the germinal centers of involved lymph nodes from CD patients [8,28] and the finding that the lymph node excision in UCD patients”
BackgroundSelf-citationUnicentric Retroperitoneal Castleman Disease Presenting with Pleural Effusion
Aa, J., Alaqqad, A., Al-Qasem, K., & Aa, D. (2017) · doi:10.4172/2161-0940.1000258 · Cited by 1
“Dysregulation of interleukin-6 (IL-6) has been implicated in the pathogenesis of plasma cell Castleman disease [3,4].”
BackgroundBoukhris, I., Zoubaidi, H., Kechaou, I., Chérif, E., Znaidi, N., Miled, A. B., & Khalfallah, N. (2016) · doi:10.12691/ajmcr-4-10-3 · Cited by 1
“There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities in CD [21].”
BackgroundUnicentric Castleman's disease: An unusual cause of neck swelling
Komaranchath, A., Rudresh, A., KuntegowdenahalliLakshmaiah, C., Premalata, C., Loknatha, D., & Jacob, L. (2015) · doi:10.5348/z10-2015-2-cr-2 · Cited by 1
“Studies in the early 1990’s have found a correlation between the systemic manifestations of unicentric Castleman’s disease and local production of Interleukin-6 [11, 12].”
BackgroundCabrera, L., Vásquez, S., Escalaya, A., Ramos, C., Bravo, F., & Venegas, D. (2012) · Revista Médica Herediana · doi:10.20453/rmh.v23i3.1031 · Cited by 1
“El virus herpes 8 codifica una citoquina homóloga a IL6, es por ello su presencia es casi una norma cuando tenemos un paciente con HIV y enfermedad de Castleman y por el contrario casi no lo encontramos en pacientes no HIV, como nuestro caso.”
InfluentialDiagnostic and Therapeutic Difficulties in Diffuse Large B-cell Lymphoma Arising From HHV8 Positive
Páyer, E., Miltényi, Z., Simon, Z., Magyari, F., Barna, S., Méhes, G., & Illés, Á. (2012) · doi:10.4021/jh27w · Cited by 1
“IL-6 is also responsible for polarization of T-lymphocytes to a type 2 cytokin profile leading to Ig production and autoimmun phenomena [12].”
BackgroundAkın, E. (2022) · Eurasian Journal of Medical Advances · doi:10.14744/ejma.2022.76486 · Cited by 1
“The critical role of inflammatory mediators such as interleukin 6 (IL-6) or interleukin 10 (IL-10) and human herpesvirus 8 (multicentric variant only) has been demonstrated in preclinical animal models.[10] The unicentric CD is most common in the chest (70%), neck (15%), and rarely in the abdomen-pelvis (12%) and axil…”
BackgroundBleiber, B., Gebbers, J., & Joss, R. (2000) · Medizinische Klinik · doi:10.1007/pl00002143 · Cited by 1
“Die schlechte Prognose ist vor allem durch gehäufte infektiöse Komplikationen und durch den Übergang in ein Non-Hodgkin-Lymphom oder ein Kaposi-Sarkom bedingt [22, 30].”
BackgroundAssessment of Interleukin-6 in the Progression of Periodontal Disease.
Takahashi, K. (1992) · doi:10.2329/perio.34.286 · Cited by 1
Multidisciplinary Collaborative Treatment of Mediastinal Castleman Disease: A Case Report
Lang, Y.-F., & Yao, J.-C. (2026) · The American journal of case reports · doi:10.12659/ajcr.953364
“MCD manifests with systemic symptoms such as fever, night sweats, fatigue, anorexia, weight loss, and hepatomegaly [13].”
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies
Nishimura, Y., Habermann, T. M., Dispenzieri, A. A., & van Rhee, F. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2702010
“Through activation of the gp130 receptor complex and downstream JAK-STAT3 signaling, IL-6 drives many of the hallmark clinical and laboratory features of iMCD, including fever, fatigue, anemia of inflammation, hypoalbuminemia, thrombocytosis, and capillary leak [22–24].”
Vasile, A., Cloșca, R., Rakitovan, M., Iordache, M., & Zară, F. (2026) · Diagnostics · doi:10.3390/diagnostics16111622
“Dysregulation of inflammatory cytokines is considered to be the primary pathological mechanism in KSHV-MCD [24–26].”
Cheng, Z.-Y., Liu, W.-L., & Hu, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1717172
Kuhn, L.-M., Graafen, L., Özdemir, E., Seidl, M., & Oommen, P. T. (2025) · Arthritis und Rheuma · doi:10.1055/a-2506-6325
Yan, J.-Y., Choi, K., Fu, P., Li, Y., & Li, Z. (2025) · BMC Neurology · doi:10.1186/s12883-025-04438-4
“Symptom improvement in Castleman disease is correlated with decreased IL-6 levels, and vice versa [35].”
Parotid Castleman’s disease: A case report and literature review
Li, X., Li, Y., Shi, H., Qin, Y.-W., Zhuang, Z., Ma, F., Chen, S., Xiao, Z., Liu, C., & Liu, W. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107713
Suzuki, K., Akiyama, M., Saito, K., Shimanuki, K., & Kaneko, Y. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2547444
“Although the precise pathogenesis of MCD remains unclear, excessive IL-6 production within the affected lymph nodes is considered a central pathogenic mechanism [2,7,8].”
Castleman’s Disease-Unicentric Neck Lymphadenoapthy: Case Report and Review of Literature
Hakeem, A., Iftikhar, N., & Padua, M. (2025) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-025-05641-y
“While others believe it be lymphoid hamartoma, but what is clear is that there is no evidence of it being an infectious disease [4].”
Clinical Features of Pulmonary Lymphoproliferative Disorders.
Tzilas, V., & Ryu, J. (2025) · Seminars in ultrasound, CT, and MR · doi:10.1053/j.sult.2025.06.006
Rapidly Progressive Joint Destruction in Idiopathic Multicentric Castleman’s Disease: A Case Report
Matsumoto, H., Matsuoka, N., Tasaki, K., Sato, N., Kuroda, M., & Miyata, M. (2025) · Cureus · doi:10.7759/cureus.85108
“Elevation of various inflammatory cytokines - especially interleukin-6 (IL-6) [3] - and abnormal activation of the mechanistic target of rapamycin (mTOR) are involved in the inflammatory pathogenesis of CD [4].”
Shima, A., Shima, T., Matsuo, C., Suehiro, T., Kamimura, T., Niiro, H., & Hirakawa, M. (2025) · Renal Replacement Therapy · doi:10.1186/s41100-025-00607-w
“Therefore, the overproduction of IL-6 is believed to play a central role in the disease’s clinical manifestations and histopathology [5].”
Liu, W., Zhang, T., Liang, R., & Hu, X. (2025) · Medicine · doi:10.1097/md.0000000000041559
Wada, T. T., Yokota, K., Okada, M., Ichimura, T., Ueno, T., Okumura, N., Osawa, I., Inoue, K., Akiyama, Y., Nakazato, Y., et al. (2024) · Internal medicine · doi:10.2169/internalmedicine.4503-24
“CD with multiple lymph node swelling is classified as MCD. Similar to NMOSD, excessive IL-6 production is strongly associated with MCD pathogenesis (6, 7).”
Atypical Combination of Mixed Connective Tissue Disease and Multicentric Castleman Disease
Saparov, D., Gold-Olufadi, S., Wasifusddin, M., Hakobyan, N., Uche, I., Becerra, H., Barakat, P., Yadav, R., Pokhrel, A., Boris, A., et al. (2024) · Cureus · doi:10.7759/cureus.70325
“The inciting factor has been postulated to be related to elevated IL-6 [9], chronic inflammation, lymphoid expansion, chronic viral infections, especially HHV-8 infections, cytokine activation, and vascular proliferation [10].”
BackgroundA rare case report of hyaline-vascular type Castleman disease in the presacral region
Chang, L., Wang, S., Li, J.-N., Zhao, Z., & Wang, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1434542
TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report
Meng, S., Liu, H.-L., Zhang, W.-G., He, A.-L., Sun, H., Zhang, R., Chen, X., & Chen, Y.-X. (2023) · Clinical Case Reports · doi:10.1002/ccr3.6183
HHV-8-associated multicentric Castleman disease with concurrent Kaposi sarcoma
Boland, J. L., Beckerman, J. K., Hanyok, B. T., Akin, E. A., & McKinnell, Z. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250228 · Cited by 1
Castleman flare or COPD exacerbation— can biomarkers override availability bias?
Claxton, B. B., Dimmock, A. E. F., Jain, R., Drummond, M., & Bascom, R. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101099
Mohamed, A. (2020) · Journal of Clinical Research and Reports · doi:10.31579/jcrr/2020/005
“Removal of mass causes an abrupt drop in IL-6 levels and resolution of symptoms (5) and the treatment with IL-6 receptor antibody relieves the clinical manifestations of the disease (6,7).”
BackgroundKobrin, D. M., & Fajgenbaum, D. (2019) · Periodic and Non-Periodic Fevers · doi:10.1007/978-3-030-19055-2_11
Anemia associated with increased hepcidin in two children with Castleman disease
Mizukami, M., Yoto, Y., Nishihori, S., Kimura, S., & Tsutsumi, H. (2018) · Pediatrics International · doi:10.1111/ped.13631
A CASE REPORT OF CASTLEMAN DISEASE
Jain, S., Agrawal, A., Singh, L., & Tandon, R. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/836
Castleman’s Disease with All Aspects: Single Center Experience with Long Term Follow-up
Atilla, F., Demir, D., Soyer, N., Tombuloǧlu, M., Vural, F., Töbü, M., Şahin, F., Özsan, N., Hekimgil, M., & Saydam, G. (2018) · LLM Dergi · doi:10.5578/llm.66759
A case of hyaline-vascular type of Castleman's disease arising in the submandibular region
Shigematsu, H., Gotoh, A., Kobayakawa, M., Kamei, K., Gotoh, Y., & Hamada, Y. (2017) · doi:10.5794/jjoms.63.439
An Unusual Case of Multicentric Castleman's Disease, Complicated by Pleural Effusion
Nozawa, S., Yasuo, M., Yamamoto, H., Hama, M., Tateishi, K., Ushiki, A., & Hanaoka, M. (2017) · doi:10.11441/shinshumedj.65.51
Sleptsova, S., Yadrichinskaya, V. N., Palchina, A. M., Borisova, N. V., Mulina, I., Parfenova, S. N., Butaev, L., & Indeeva, L. D. (2016) · doi:10.21103/article6(2)_crep1
“IL-6 has emerged as a therapeutic target in Castleman disease based on its critical role in pathogenesis and driving of symptomatology.[32,33] When based on the clinical and pathological subtypes of Castleman’s disease, clinical manifestation and management of the disease are distinct.”
BackgroundMuhammedBasheerK, T., Mishra, S., Mishra, P., & Behera, N. (2015) · doi:10.7439/ijbar.v6i11.2656
“com Several immunological mechanisms have been proposed including over production of interlukin-6 and human herpes virus type -8 infections.[3,7,8] Interestingly, HIV status may influence the constellation of signs and symptoms in MCD patients: based on epidemiologic data from the pre- and post-HIV eras, HIV-negative…”
BackgroundAn unusual case of intrathoracic Castleman’s Disease
Schoon, R., Mulroy, L., Xu, Z.-L., & Bethune, D. (2015) · doi:10.15273/dmj.vol42no1.6437
Kaur, H., Xiang, Z., Kunthur, A., & Mehta, P. (2015) · Federal practitioner : for the health care professionals of the VA, DoD, and PHS · doi:10.53347/rid-40917
“Correlation between the patient serum level of IL-6 and the severity of symptoms, size of lymph nodes and amount of lymphadenopathy has been demonstrated.(3)”
BackgroundQin, A.-Y., Ren, X.-B., & Cao, S. (2014) · doi:10.1016/j.achaem.2014.03.001
“[15] Yoshizaki K, Matsuda T, Nishimoto N, et al.”
BackgroundA Case of Localized Castleman's Disease in a Patient with Rheumatoid Arthritis
Choi, Y., Ku, K., Kwon, H., Park, D.-H., & Kim, G.-T. (2012) · doi:10.4078/jrd.2012.19.6.351
“전신형의 경우 치료방침이 정립되 어 있지 않으나 스테로이드를 이용한 전신치료나 항암화학 요법 또는 이 둘의 병합치료가 시도되고 있으며 (14) 최근에 는 IL-6에 대한 항체나 TNF-alpha를 사용하기도 한다 (15).”
InfluentialTanaka, T., Hagihara, K., Shima, Y., Narazaki, M., Ogata, A., & Kumanogoh, A. (2011) · Drug Development Research · doi:10.1002/ddr.20480
“Moreover, IL-6 was highly expressed in hyperplastic lymph nodes of patients with Castleman’s disease; surgical removal of the solitary involved lymph node led to clinical improvement and reduction of serum IL-6 levels [Yoshizaki et al., 1989].”
BackgroundMesenteric Castleman’s disease- a case report
Hasan, M., Siddiqui, F., Gaur, K., & Naim, M. (2008) · doi:10.5580/340
Sousa, V., & Carvalho, L. (2006) · doi:10.1016/s2173-5115(06)70402-x
Diagnostik und Therapie des Morbus Castleman
Pontenagel, U., & Ulrich, B. (2004) · doi:10.1055/s-2004-823164
Teymoortash, A., Lippert, B., Ramaswamy, A., Bien, S., & Werner, J. (2001) · doi:10.1055/s-2001-17089
LABORATORY CHARACTERIZATION OF MALIGNANCIES OF THE IMMUNE SYSTEM
Janik, J., & Longo, D. (1994) · Immunology and allergy clinics of North America · doi:10.1016/s0889-8561(22)00776-7
Study on cytokines produced by cystic tissues in the jaw
Okitsu, M. (1993) · doi:10.5794/jjoms.39.353
A Case Report on Idiopathic-Multi-centric Castleman’s Disease Associated POEMS- Syndrome
Nair, A. R., Gichin, C., Santhi, D. P. R., & Savithri, M. C. (2022) · International Journal of Clinical Oncology and Cancer Research · doi:10.11648/j.ijcocr.20220701.13
“Although; most of the time, treatment is focused on immunosuppression and immunomodulation with steroids and chemotherapeutic agents respectively [7, 8].”
BackgroundViruses and Human Cancer: From Basic Science to Clinical Prevention
Krämer, A., Lu, J., Wu, T.-C., Chang, M.-H., Jeang, K., Lowy, D. R., Chen, C.-J., You, S., Hsu, W.-L., Yang, H. I., et al. (2021) · Recent Results in Cancer Research · doi:10.1007/978-3-030-57362-1
“In MCD patients, levels of IL-6 are substantially higher in affected lymph nodes when compared to unaffected nodes of the same patient (Yoshizaki et al. 1989).”
Gillis, N., Moscinski, L. C., & Padron, E. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_57-1 · Cited by 1
Targeting Interleukin-6 in Ocular Inflammatory Diseases
Mesquida, M., Llorenç, V., & Adán, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-22827-9_9
A case of lung cancer complicated by axillary Castleman's disease
Kakizoe, M., Suzuki, K., & Saeki, N. (2015) · doi:10.2995/jacsurg.29.722
Sachin, B., Anshu, G., Maneesh, G., Anurag, G., & Deepa, R. (2013) · doi:10.9790/0853-0615558
ヒト型化抗IL-6レセプター抗体を用いたIL-6シグナル伝達阻害によるキャッスルマン病の治療への応用
吉崎, 和., 西本, 憲., ひろみ, 田., & 松本, 智. (1998) · doi:10.2492/jsir1981.18.319
Self-citationCastleman's Disease of the Neck : A Case Report
Yoshizaki, T., Kobayashi, Y., Katada, A., Hayashi, T., Imada, M., Nonaka, S., & Harabuchi, Y. (2001) · doi:10.5631/jibirin.94.929
Bromberg, P. A., & Rivera, M. P. (1999) · Springer eBooks · doi:10.1007/978-1-4471-3440-4_13 · Cited by 1
“Many of the clinical manifestations of the systemic form of the disease may be related to ele vated levels ofIL-6 [214,215].”
Zhu, G.-G., Kauppila, A., Risteli, L., Mäkinen, M., Stenbäck, F., & Risteli, J. (1995) · Cancer · doi:10.1002/1097-0142(19950215)75:4
Metadata
- Authors
- Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T.
- Affiliations
- The University of Osaka (JP)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1989-09-01
- Volume
- 74
- Issue
- 4
- Pages
- 1360-1367
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1632068222
- Cited by
- 928
- References
- 0
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 23 · 2023: 15 · 2022: 29 · 2021: 20 · 2020: 32 · 2019: 18 · 2018: 33 · 2017: 37 · 2016: 21 · 2015: 38 · 2014: 35 · 2013: 34 · 2012: 25
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- Castleman disease, interleukin-6, germinal center, B cells, lymph node hyperplasia, hypergammaglobulinemia, acute phase proteins, plasma cell infiltration, surgical resection, cytokine production
- MeSH terms
- Adolescent, Female, Castleman Disease, Humans, Interleukins, Lymph Node Excision, Lymph Nodes, Lymphatic Diseases, Middle Aged, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
